# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN-TD
- Date: 1980-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: antibody, nerve stimulation and imaging results; neuromuscular neurology seen today. **S**

## History of present illness

Ms. Mankiller returns two weeks after her first visit. On pyridostigmine 30 mg three times daily her eyelids lift for two to three hours after each dose, but double vision returns by evening and her arms still tire when she brushes her hair; she has mild stomach cramps and looser stools after doses. She has had no breathlessness, choking or weak cough. The acetylcholine receptor antibody test is strongly positive. The chest CT and kidney ultrasound were done last week. This morning she saw Dr. Okafor-Delaney of neuromuscular neurology, whose nerve stimulation test showed the typical decrement, and they agreed a plan: a higher pyridostigmine dose, prednisone started low and raised slowly, azathioprine once the screening tests are back, and an assessment for thymectomy. She asked that her blood tests be drawn near home where possible, and wants to understand each medicine before she takes it. She says the polycystic kidney disease is not new to her. **S**

| Element | Detail |
|---|---|
| Diagnosis | Generalized myasthenia gravis, AChR antibody 6.8 nmol/L, decrement on nerve stimulation; MGFA class IIa; MG-ADL 7 |
| Imaging | No thymoma on chest CT; kidney ultrasound: polycystic kidneys, Mayo Imaging Class 1B |
| Starting today | Pyridostigmine 60 mg four times daily; prednisone 10 mg rising weekly; calcium and vitamin D |
| Vaccines today | PCV20 and recombinant zoster dose 1, before immunosuppression |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Drooping eyelids and double vision by evening |
| Musculoskeletal | Positive | Arms and neck tire with use; leg aches after the operations |
| Gastrointestinal | Positive | Cramps and loose stools after pyridostigmine; no trouble swallowing |
| Respiratory | Negative | No breathlessness lying flat; cough strong |
| Psychiatric | Negative | Worried but coping; PHQ-2 score 1 |

5 systems reviewed. **S**

## Current medications

- Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals **S**
- Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg **S**
- Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food **S**
- Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/80 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 61.6 kg; BMI 23.2 kg/m². All vital signs are synthetic.

Acetylcholine receptor binding antibody: 6.8 nmol/L (high); Forced vital capacity (seated): 3.25 L; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Forced vital capacity (seated): 3.3 L at baseline, 3.25 L at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20, before immunosuppression **S**
- Recombinant zoster vaccine, dose 1 of 2, before immunosuppression **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/80 mm Hg |
| Eyes | Left ptosis after 40 seconds of upgaze; diplopia on sustained right gaze |
| Neurological | Neck flexion 4 of 5; deltoids fatigue after 45 seconds of arm abduction; speech becomes nasal after counting to 40; reflexes normal |
| Respiratory | Single-breath count to 30; FVC 3.25 L |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Generalized myasthenia gravis, AChR antibody positive, MGFA class IIa** (G70.00). The diagnosis is confirmed by the antibody and the nerve stimulation decrement; MuSK antibodies and single-fiber EMG are not needed. No thymoma. FVC 3.25 L and negative inspiratory force -68 cm H2O: no sign of impending crisis. **S**
   - Pyridostigmine 60 mg four times daily while awake, before meals.
   - Prednisone 10 mg each morning, raised by 10 mg each week to 40 mg.
   - Azathioprine after TPMT activity and hepatitis B and tuberculosis screening, drawn today.
   - Thoracic surgery assessment for robotic thymectomy once stable.
   - Crisis warning signs and the list of medicines to avoid reviewed again.
2. **Starting glucocorticoids** (Z79.52). Baseline hemoglobin A1c 5.3 percent, blood pressure 124/80 mm Hg, weight 61.6 kg; a slow start lowers the risk of early worsening. **S**
   - Calcium carbonate 1250 mg and cholecalciferol 1000 units daily.
   - DXA at the next visit.
   - Glucose, blood pressure and weight at each visit.
3. **Autosomal dominant polycystic kidney disease** (Q61.2). Both kidneys enlarged with many cysts; height-adjusted total kidney volume 364 mL/m at 34, Mayo Imaging Class 1B, not rapidly progressive, so tolvaptan is not indicated. eGFR 102 and urine albumin 14 mg/g at the first visit; blood pressure normal-high. **S**
   - Home blood pressure readings twice a week; target 110/75 mm Hg or lower if readings exceed 130/85.
   - Water 2 to 3 liters a day; less salt; no NSAIDs.
   - eGFR and urine albumin yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Acetylcholine receptor binding antibodies | At diagnosis | Completed today | 6.8 nmol/L, positive (drawn at the first visit) |
| Laboratory | MuSK antibodies | If AChR antibodies are negative | Not indicated | AChR antibodies positive |
| Examination | Repetitive nerve stimulation | At diagnosis | Completed today | 22 percent decrement in the nasalis and 18 percent in the trapezius at neuromuscular neurology |
| Examination | Single-fiber EMG | If antibodies and nerve stimulation are not diagnostic | Not indicated | Diagnosis already confirmed |
| Imaging | CT of the chest for thymoma | At diagnosis | Up to date | Five days ago: no thymoma; residual thymic tissue for age |
| Laboratory | TSH | At diagnosis | Up to date | 1.9 mIU/L at the first visit |
| Imaging | Forced vital capacity and negative inspiratory force | Every visit while weak, and with any breathing or swallowing symptom | Completed today | FVC 3.25 L; negative inspiratory force -68 cm H2O; single-breath count 30 |
| Examination | Myasthenic crisis warning signs | Every visit | Completed today | No breathlessness lying flat, weak cough, choking or slurred speech; reviewed again with her |
| Survey | MG-ADL score | Every visit | Completed today | 7 of 24 (eyelids, double vision, chewing, brushing hair); no LOINC code, so recorded here |
| Survey | Depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Medication safety | Pyridostigmine side effects | Every visit | Completed today | Cramps and loose stools, mild; taken before meals |
| Medication safety | Medicines that can worsen myasthenia gravis | At diagnosis and with every new prescription | Completed today | Wallet card and list given: fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers, telithromycin and others |
| Laboratory | Screening before immunosuppression: hepatitis B, tuberculosis and TPMT | Before azathioprine | Ordered | Drawn today at the clinic |
| Laboratory | Hemoglobin A1c before glucocorticoids | Baseline, then periodically | Up to date | 5.3 percent at the first visit |
| Medication safety | Vaccination before immunosuppression | Before starting immunosuppressive drugs | Completed today | PCV20 and recombinant zoster dose 1 today; no live vaccines from now on |
| Medication safety | Pregnancy and contraception on prednisone and azathioprine | Before starting and yearly | Completed today | Urine pregnancy test negative; she reports reliable contraception; pregnancy to be planned with neuromuscular neurology |
| Laboratory | eGFR and urine albumin-to-creatinine ratio | Yearly in ADPKD with normal function | Up to date | eGFR 102 and urine albumin 14 mg/g at the first visit |
| Imaging | Kidney imaging with total kidney volume (Mayo Imaging Classification) | At diagnosis or first assessment | Up to date | Ultrasound five days ago: htTKV 364 mL/m, class 1B; tolvaptan not indicated |
| Examination | Blood pressure | Every visit | Completed today | 124/80 mm Hg in clinic; home readings to start |
| Referral | Neuromuscular neurology | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Referral | Thoracic surgery for thymectomy | Once stable | Ordered | Assessment visit in about four weeks |
| Self-management | Home blood pressure, water intake, salt, and care close to home | Every visit | Completed today | Home monitor shown; blood tests to be drawn at the Cherokee Nation clinic near her home where possible |

## Goal progress

- A confirmed diagnosis and treatment plan within three weeks. Outcome by 1980-03-23: AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks. **S**
- Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less. In progress; target 1980-10-12. **S**
- No myasthenic crisis, and she knows the warning signs and the medicines to avoid. In progress; target 1980-10-12. **S**
- Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs. In progress; target 1980-10-12. **S**
- Return to full-time work for the Cherokee Nation. In progress; target 1980-10-12. **S**

## Medication changes

- Stopped: Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating **S**
- Started: Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals **S**
- Started: Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg **S**
- Started: Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food **S**
- Started: Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily **S**

## Guideline basis

- Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020), Myasthenia Gravis Foundation of America task force (Neurology)
- Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016), Myasthenia Gravis Foundation of America task force (Neurology)
- Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026), Myasthenia Gravis Foundation of America
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025), Kidney Disease: Improving Global Outcomes (KDIGO)

## Follow-up

- Neuromuscular neurology nurse call in one week as prednisone rises. Thoracic surgery assessment in about four weeks. Review here in six weeks with blood count, chemistry, FVC and DXA. **S**
- Next scheduled visit 1980-05-04: six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan. **S**
